HIGHLIGHTS
- who: Xintong Hou from the UND Life Sciences LLC, United States Ulster University, United Kingdom have published the research work: Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes, in the Journal: (JOURNAL)
- what: Novel drug discovery and development of VIP analogues as well as a suitable drug delivery system are the main goals in developing VIP as hypoglycemic drugs.
- how: To demonstrate the role of vagal signals in the liver-brain- pancreas neuronal relay mouse islets were treated with a combination of neurotransmitters released from vagus nerves . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.